These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 37961860

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, Beltrami G, Scoccianti G, D'Arienzo A, Capanna R, Franchi A.
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [Abstract] [Full Text] [Related]

  • 4. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I.
    Clin Cancer Res; 2012 Aug 15; 18(16):4415-24. PubMed ID: 22711702
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
    Yamagishi T, Kawashima H, Ogose A, Ariizumi T, Sasaki T, Hatano H, Hotta T, Endo N.
    PLoS One; 2016 Aug 15; 11(5):e0154680. PubMed ID: 27163152
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumor Effects of Cyclolinopeptide on Giant-cell Tumor of the Bone.
    Taniguchi Y, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Higuchi T, Abe K, Yonezawa H, Araki Y, Morinaga S, Kamei J, Nugroho AE, Kaneda T, Morita H, Tsuchiya H.
    Anticancer Res; 2019 Nov 15; 39(11):6145-6153. PubMed ID: 31704842
    [Abstract] [Full Text] [Related]

  • 8. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
    Shibuya I, Takami M, Miyamoto A, Karakawa A, Dezawa A, Nakamura S, Kamijo R.
    Pathol Oncol Res; 2019 Jan 15; 25(1):409-419. PubMed ID: 29159783
    [Abstract] [Full Text] [Related]

  • 9. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL, Hansen RL, Jørgensen PH.
    Ugeskr Laeger; 2016 Sep 05; 178(36):. PubMed ID: 27593237
    [Abstract] [Full Text] [Related]

  • 10. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
    Ud Din N, Umer M, Park YK.
    Int J Surg Pathol; 2020 Dec 05; 28(8):859-867. PubMed ID: 32429739
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment.
    Noguchi T, Sakamoto A, Murotani Y, Murata K, Hirata M, Yamada Y, Toguchida J, Matsuda S.
    J Histochem Cytochem; 2023 Mar 05; 71(3):131-138. PubMed ID: 36971322
    [Abstract] [Full Text] [Related]

  • 12. Denosumab for the treatment of giant cell tumor of the bone.
    Brodowicz T, Hemetsberger M, Windhager R.
    Future Oncol; 2015 Mar 05; 11(13):1881-94. PubMed ID: 26161925
    [Abstract] [Full Text] [Related]

  • 13. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
    Cowan RW, Singh G, Ghert M.
    J Orthop Res; 2012 Jun 05; 30(6):877-84. PubMed ID: 22102368
    [Abstract] [Full Text] [Related]

  • 14. Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.
    Rosario M, Takeuchi A, Yamamoto N, Hayashi K, Miwa S, Higuchi T, Abe K, Taniguchi Y, Aiba H, Tanzawa Y, Murakami H, Tsuchiya H.
    Anticancer Res; 2017 Feb 05; 37(2):749-754. PubMed ID: 28179326
    [Abstract] [Full Text] [Related]

  • 15. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I, Furuya M, Matsuo K, Kawabata Y, Tanaka R, Ohashi K.
    Histopathology; 2018 May 05; 72(6):914-922. PubMed ID: 29206281
    [Abstract] [Full Text] [Related]

  • 16. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
    Federman N, Brien EW, Narasimhan V, Dry SM, Sodhi M, Chawla SP.
    Paediatr Drugs; 2014 Feb 05; 16(1):21-8. PubMed ID: 24114694
    [Abstract] [Full Text] [Related]

  • 17. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
    Tariq MU, Umer M, Khan Z, Saeed J, Siddiqui MA, Din NU.
    Ann Diagn Pathol; 2020 Apr 05; 45():151479. PubMed ID: 32088577
    [Abstract] [Full Text] [Related]

  • 18. The clinical approach toward giant cell tumor of bone.
    van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, Bovée JV, Hogendoorn PC, Gelderblom H.
    Oncologist; 2014 May 05; 19(5):550-61. PubMed ID: 24718514
    [Abstract] [Full Text] [Related]

  • 19. A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab.
    Mak IW, Evaniew N, Popovic S, Tozer R, Ghert M.
    J Bone Joint Surg Am; 2014 Aug 06; 96(15):e127. PubMed ID: 25100780
    [Abstract] [Full Text] [Related]

  • 20. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.
    Toda Y, Kohashi K, Yamamoto H, Ishihara S, Ito Y, Susuki Y, Kawaguchi K, Kiyozawa D, Takamatsu D, Kinoshita I, Yamada Y, Maehara J, Kimura A, Tamiya S, Taguchi K, Matsunobu T, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y.
    Sci Rep; 2021 Jul 20; 11(1):14821. PubMed ID: 34285260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.